Claims

1) Synthesised cyclosporin characterised by the formula:

-X-U-Y-Z-Val-MeLeu-Ala-(D)Ala-MeLeu-MeLeu-MeVal-
1 2 3 4 5 6 7 8 9 10 11

wherein:

X is -MeBmt or 6,7-dihydro-MeBmt-

U is -Abu, Nva, Val, Thr

Y is Sar or (D)-MeSer or (D)-MeAla or (D)-MeSer (OAcyl)

Z is (N-R)aa where aa={Val, Ile, Thr, Phe, Tyr, Thr (OAc), Thr (OG_1), Phe (G_2), $PheCH_2(G_3)$, Tyr (OG_3)} with R = {alkyl > CH_3};

G_1 = {phenyl-COOH, phenyl-COOMe, phenyl-COOEt};

G_2 = {CH_2COOH, $CH_2COOMe(Et)_4$; $CH_2PO(OMe)_2$, $CH_2PO(OH)_2$};

G_3 = {$PO(CH)_2$, $PO(OCH_2CH=CH_2)_2$, CH_2COOH, $CH_2COOMe(Et)$}.

2) Cyclosporin according to claim 1, characterised in that the residue Z in position 4 is (R)Val where R>CH_3 and R<$C_{10}H_{21}$.

3) Cyclosporin according to any one of the preceding claims, characterised in that the residue Z in position 4 is N-ethyl-valine.

4) Pharmaceutical composition containing the compound characterised by the formula:

```
|-X-U-Y-Z-Val-MeLeu-Ala-(D)Ala-MeLeu-MeLeu-MeVal-|
|                                                 |
| 1 2 3 4  5    6    7     8      9    10    11  |
---------------------------------------------------
```

wherein:

X is -MeBmt or 6,7-dihydro-MeBmt-

U is -Abu, Nva, Val, Thr

Y is Sar or (D)-MeSer or (D)-MeAla or (D)-MeSer (OAcyl)

Z is (N-R)aa where aa={Val, Ile, Thr, Phe, Tyr, Thr (OAc), Thr (OG_1), Phe (G_1), PheCH_2(G_2), Tyr (OG_3)} with R = {alkyl > CH_3};

G_1 = {phenyl-COOH, phenyl-COOMe, phenyl-COOEt};

G_2 = {CH_2COOH, $CH_2COOMe(Et)$, $CH_2PO(OMe)_2$, $CH_2PO(OH)_2$};

G_3 = {$PO(OH)_2$, $PO(OCH_2CH=CH_2)_2$, CH_2COOH, $CH_2COOMe(Et)$}

5) Pharmaceutical composition according to claim 4, characterised in that it is combined with a pharmaceutically acceptable solution.

6) Use of the cyclosporin according to any one of the preceding claims for the production of a medicinal product intended for the treatment and prevention of AIDS.

7) Use of the cyclosporin according to claim 3 for the production of a medicinal product intended for the treatment and prevention of AIDS.